A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients

Annals of Oncology

Volumn 25, Issue 3, 2014, Pages 638-643

  Honing, J ^a   Smit, J K ^a   Muijs, C T ^a   Burgerhof, J G M ^a   De groot, J W ^b   Paardekooper, G ^b   Muller, K ^c   Woutersen, D ^d   Legdeur, M J C ^d   Fiets, W E ^e   Slot, A ^f   Beukema, J C ^a   Plukker, J Th M ^a   Hospers, G A P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

^c Radiation Oncology Institute Stedendriehoek en Omstreken   (Netherlands)

^d MEDISCH SPECTRUM TWENTE   (Netherlands)

^e MEDICAL CENTER LEEUWARDEN   (Netherlands)

^f Radiotherapeutic Institute Friesland   (Netherlands)

Author keywords

Cancer; Carboplatin; Chemoradiation; Definitive; Esophageal; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN PLUS PACLITAXEL; CISPLATIN PLUS FLUOROURACIL; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; BLEEDING; BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; FATIGUE; FEBRILE LEUKOPENIA; FEMALE; HUMAN; HUMAN TISSUE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; NAUSEA; NETHERLANDS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA; TUMOR VOLUME; VOMITING;

CANCER; CARBOPLATIN; CHEMORADIATION; DEFINITIVE; ESOPHAGEAL; PACLITAXEL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 84896807599     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt589     Document Type: Article

References (16)

1. Crane LM, Schaapveld M, Visser O et al. Oesophageal cancer in The Netherlands: increasing incidence and mortality but improving survival. Eur J Cancer 2007; 43: 1445-1451.
2. Dutch Cancer Registration. Survival of esophageal cancer patients in the Netherlands. 2005; www.cijfersoverkanker.nl/selecties/Dataset_2/img512d09a0bce07 (8 September 2013, data last accessed).
3. Lepage C, Rachet B, Jooste V et al. Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol 2008; 103: 2694-2699.
4. Pennathur A, Gibson MK, Jobe BA et al. Oesophageal carcinoma. Lancet 2013; 381: 400-412.
5. Sjoquist KM, Burmeister BH, Smithers BM et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692.
6. van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084.
7. Cooper JS, Guo MD, Herskovic A et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623-1627.
8. Herskovic A, Martz K, al-Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-1598.
9. Stahl M, Budach W, Meyer HJ et al. Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v46-v49.
10. National Comprehensive Cancer Network. Clinical Practical Guidelines in Oncology. Esophageal and Esophagogastric Junction Cancers (excluding the proximal 5 cm of the stomach). Version 2.2013. 2013: ESOPH-E 6.
11. Smit JK, Muijs CT, Burgerhof JG et al. Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands. Ann Surg Oncol 2013; 20: 1985-1992.
12. Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol 2003; 21: 19-22.
13. Polee MB, Sparreboom A, Eskens FA et al. A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer. Clin Cancer Res 2004; 10: 1928-1934.
14. Wang H, Ryu J, Gandara D et al. A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer. J Thorac Oncol 2007; 2: 153-157.
15. Courrech Staal EF, Aleman BM, van Velthuysen ML et al. Chemoradiation for esophageal cancer: institutional experience with three different regimens. Am J Clin Oncol 2011; 34: 343-349.
16. Blom RL, Sosef MN, Nap M et al. Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma. Dis Esophagus 2013 [epub ahead of print].